SCHEMBL2882722

SCHEMBL2882722

C[Si](C)(C)CCOCn1cc(Cl)c2c(Cc3ccc(NC(=O)C(F)(F)F)cc3F)ccnc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
MET P08581 1/20 0.34
BRAF P15056 3/20 0.33
MAPT P10636 2/20 0.33
AR P10275 1/20 0.33
RET P07949 3/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
KDR P35968 2/20 0.32
DGAT1 O75907 2/20 0.32
ABL1 P00519 1/20 0.32
LCK P06239 1/20 0.32
CSF1R P07333 1/20 0.32
LYN P07948 1/20 0.32
KIT P10721 1/20 0.32
SRC P12931 1/20 0.32
FLT1 P17948 1/20 0.32
FLT4 P35916 1/20 0.32
FLT3 P36888 1/20 0.32
BLK P51451 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2885789 0.91 MET (0.34) EPHX2NR1H4METBRAFMAPT
SCHEMBL2882862 0.85 MET (0.37) EPHX2NR1H4METBRAFMAPT
SCHEMBL25245487 0.76 RET (0.41) METRETKDR
SCHEMBL4767990 0.75 ROCK2 (0.35) METBRAFDGAT1
SCHEMBL25793123 0.75 KDR (0.40) METBRAFRETKDR
SCHEMBL20587892 0.74 ROCK2 (0.43) METRETKDRDGAT1CSF1R
SCHEMBL20587979 0.73 ROCK2 (0.40) METBRAFRETKDR
SCHEMBL20588408 0.73 ROCK2 (0.44) METRETKDRDGAT1CSF1R
SCHEMBL23644677 0.73 RET (0.41) BRAFRETKDR
SCHEMBL20589044 0.72 RET (0.40) BRAFRETKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
EP-1742945-B1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER SCHERING PHARMA AG (DE) 2009-12-30 EP disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
EP-1742945-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES Bayer HealthCare AG (DE) 2007-01-17 EP disclosed
WO-2005108397-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER HEALTHCARE AG (DE) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269268-A1 Substituted Phenylamino-Pyrimidines TYMP, DPYD, HPRT1 EPHX2 1511/4885NR1H4 1367/4885MET 3468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.